Literature DB >> 18301061

Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals.

Jessica L Long1, Eric A Engels, Richard D Moore, Kelly A Gebo.   

Abstract

OBJECTIVE: To investigate trends, patient characteristics, and survival associated with AIDS-defining cancer (ADC) and non-AIDS defining cancer (NADC) in the HAART era.
DESIGN: Retrospective analysis of all incident malignancies occurring in 1996-2005 among 2566 patients in an urban HIV clinic.
METHODS: Clinical profiles of NADC were compared with ADC and the general cohort. Incidence was examined by Poisson analysis. Standardized incidence ratios (SIR) compared cancer risk with that in the general population. Survival was analyzed by Kaplan-Meier and Cox proportional hazards models.
RESULTS: Between 1996 and 2005, 138 ADC and 115 NADC were diagnosed. ADC rates decreased from 12.5 to 3.5 cases/1000 person-years (P < 0.001 for trend) while NADC rates increased from 3.9 to 7.1 cases/1000 person-years (P = 0.13 for trend). Incidence of the most common NADC was higher than expected, including cancers of the lung [n = 29; SIR, 5.5; 95% confidence interval (CI), 3.7-8.0], liver (n = 13, SIR, 16.5; 95% CI, 8.8-28.2), anus (n = 10; SIR, 39.0; 95% CI, 18.7-71.7), head and neck (n = 14; SIR, 5.1; 95% CI, 2.8-8.6), and Hodgkin's lymphoma (n = 8; SIR, 9.8; 95% CI, 4.2-19.2). Survival after cancer diagnosis did not differ between ADC and NADC. Advanced age was associated with NADC (P < 0.01 for trend) and increased mortality in ADC (age > or = 50 years adjusted hazard ratio, 2.21; 95% CI, 1.00-4.89).
CONCLUSIONS: Rates of ADC decreased while NADC increased within this cohort. Several NADC occurred at rates significantly higher than expected. Screening and suspicion for NADC should increase in care for HIV-infected patients.

Entities:  

Mesh:

Year:  2008        PMID: 18301061      PMCID: PMC2553213          DOI: 10.1097/QAD.0b013e3282f47082

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  30 in total

1.  Association of cancer with AIDS-related immunosuppression in adults.

Authors:  M Frisch; R J Biggar; E A Engels; J J Goedert
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.

Authors:  M Frisch; R J Biggar; J J Goedert
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

3.  Immune deficiency and risk for malignancy among persons with AIDS.

Authors:  Sam M Mbulaiteye; Robert J Biggar; James J Goedert; Eric A Engels
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-15       Impact factor: 3.731

4.  Cancer incidence in New York State acquired immunodeficiency syndrome patients.

Authors:  B Gallagher; Z Wang; M J Schymura; A Kahn; E J Fordyce
Journal:  Am J Epidemiol       Date:  2001-09-15       Impact factor: 4.897

Review 5.  AIDS malignancies in the era of highly active antiretroviral therapy.

Authors:  Amy E Gates; Lawrence D Kaplan
Journal:  Oncology (Williston Park)       Date:  2002-04       Impact factor: 2.990

6.  Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998.

Authors:  Janice K Louie; Ling Chin Hsu; Dennis H Osmond; Mitchell H Katz; Sandra K Schwarcz
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

7.  Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.

Authors:  Magid Herida; Murielle Mary-Krause; Régis Kaphan; Jacques Cadranel; Isabelle Poizot-Martin; Christian Rabaud; Nathalie Plaisance; Hervé Tissot-Dupont; François Boue; Jean-Marie Lang; Dominique Costagliola
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

Review 8.  AIDS and older Americans at the end of the Twentieth Century.

Authors:  Karin A Mack; Marcia G Ory
Journal:  J Acquir Immune Defic Syndr       Date:  2003-06-01       Impact factor: 3.731

9.  Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.

Authors:  Gianni E D'Egidio; Stephen Kravcik; Curtis L Cooper; D William Cameron; Dean A Fergusson; Jonathan B Angel
Journal:  AIDS       Date:  2007-08-20       Impact factor: 4.177

10.  Cancer risk in elderly persons with HIV/AIDS.

Authors:  Robert J Biggar; Katharine A Kirby; Jonnae Atkinson; Timothy S McNeel; Eric Engels
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

View more
  65 in total

1.  Age at cancer diagnosis among persons with AIDS in the United States.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Eric A Engels
Journal:  Ann Intern Med       Date:  2010-10-05       Impact factor: 25.391

Review 2.  Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings.

Authors:  Aggrey S Semeere; Naftali Busakhala; Jeffrey N Martin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

3.  A new prognostic score for AIDS-related lymphomas in the rituximab-era.

Authors:  Stefan K Barta; Xiaonan Xue; Dan Wang; Jeannette Y Lee; Lawrence D Kaplan; Josep-Maria Ribera; Albert Oriol; Michele Spina; Umberto Tirelli; Francois Boue; Wyndham H Wilson; Christoph Wyen; Kieron Dunleavy; Ariela Noy; Joseph A Sparano
Journal:  Haematologica       Date:  2014-08-22       Impact factor: 9.941

4.  Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.

Authors:  Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

Review 5.  Epidemic of lung cancer in patients with HIV infection.

Authors:  Tiffany A Winstone; S F Paul Man; Mark Hull; Julio S Montaner; Don D Sin
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

6.  Malignancies Trends in a Hispanic Cohort of HIV Persons in Puerto Rico before and after cART.

Authors:  Angel M Mayor; Eduardo J Santiago-Rodriguez; Eddy Rios-Olivares; Guillermo Tortolero-Luna; Robert F Hunter-Mellado
Journal:  Int J Cancer Res       Date:  2016-03-15

7.  A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals.

Authors:  Meredith S Shiels; Stephen R Cole; Gregory D Kirk; Charles Poole
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

8.  Spectrum of malignancies among HIV-infected patients in South India.

Authors:  K K Venkatesh; S Saghayam; B Devaleenal; S Poongulali; T P Flanigan; K H Mayer; N Kumarasamy
Journal:  Indian J Cancer       Date:  2012 Jan-Mar       Impact factor: 1.224

9.  Treatment of high-grade anal dysplasia in high-risk patients: outcome at an urban community health centre.

Authors:  S A Assoumou; L A Panther; Y Feng; R S Gelman; D K Fugelso; K H Mayer
Journal:  Int J STD AIDS       Date:  2013-05-06       Impact factor: 1.359

10.  Malignancies in human immunodeficiency virus infected patients in India: Initial experience in the HAART era.

Authors:  Surendra K Sharma; Manish Soneja; Sanjay Ranjan
Journal:  Indian J Med Res       Date:  2015-11       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.